{
    "success": true,
    "data": {
        "leverage": true,
        "derivatives": true,
        "swaps": true,
        "inverse": true,
        "replication_method": "synthetic",
        "ucits": false,
        "type": "ETP",
        "complex_factors": [
            "Inverse Strategy",
            "Leverage (implied by inverse exposure)",
            "Daily Rebalancing Compounding Effect",
            "Derivative-like Structure",
            "Explicit Comprehension Alert",
            "Targeted at Sophisticated Investors",
            "Collateralised Securities/Margin Account"
        ],
        "classification": "complex",
        "supporting_data": "The product is classified as 'complex' for several reasons, directly aligning with MiFID II and ESMA guidelines for assessing financial instruments, especially non-UCITS products. Firstly, the product is explicitly identified as 'ETP Securities' and does not claim to be UCITS compliant, immediately negating the UCITS presumption of non-complexity. Secondly, its objective is to provide '-1 times the value of the daily performance' of the underlying asset, which is an inverse strategy. This type of strategy inherently involves leverage (in the sense of magnified returns/losses) and is typically achieved through derivative instruments (e.g., futures, swaps, or short selling combined with cash management), even if not explicitly named as 'swaps' in the KID. The ESMA guidance (CESR/09-295, Section 6, Annex I) clearly states that instruments that fall under Article 4(1)(18)(c) of MiFID (giving rise to cash settlement determined by reference to indices or measures) or are MiFID-scope derivatives (Section C of Annex I, points 4-10) are 'always complex'. An inverse product falls under these categories due to its synthetic nature and dependence on a reference measure. The product's description of holding 'underlying assets in respect of this product are held in the margin account' and mentioning 'securities loans' further indicates a synthetic replication method, not physical, to achieve the inverse exposure. Thirdly, the product includes a prominent 'You are about to purchase a product that is not simple and may be difficult to understand' alert, which is a mandatory comprehension alert for complex products under MiFID II. This explicit warning is a definitive indicator of complexity. Fourthly, the KID clearly states the product is 'intended for sophisticated investors' who 'understand the risk of compounded returns and the increased risk of investment in inverse leveraged products.' The 'Compounding Effect' is also explained, highlighting that holding the product for more than one day is likely to result in a return 'different to -1 times the return of the Reference Asset,' which is a key characteristic of daily rebalanced leveraged/inverse products that adds significant complexity and risk for retail investors, particularly over longer holding periods. Lastly, its high-risk rating (Class 6 out of 7) and daily rebalancing nature underscore its complexity. The absence of capital protection is standard for market-linked products and does not, in itself, contribute to complexity, but the overall structure and intended investor profile do. The collateralisation through a margin account and securities loans, while providing security, also forms part of a structure that requires a deeper understanding than simple physical replication."
    }
}